http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S592686-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y111-02002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-08
filingDate 1982-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14691db03eab0df672b57f9be7890e4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c28ece987b4fb7ff53db863b9e66abac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c11865668661cbc4d7b42e4e52b4d878
publicationDate 1984-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S592686-A
titleOfInvention Powder pharmaceutical preparation of myeloperoxidase
abstract PURPOSE: A powder pharmaceutical preparation for suppressing reduction in activity with time during lyophilization and storage period, having increased solubility, obtained by adding citric acid (citrate) to myeloperoxidase. n CONSTITUTION: Myeloperoxidase is blended with citric acid or its salt (e.g., trisodium citrate, etc.) in an amount sufficient for its stability, to give a powder pharmaceutical preparation. A drug composition consisting essentially of myeloperoxidase shows a tendency to be unstable to lyophilization. When lyophilization is carried out, it is observed that myeloperoxidase activity is reduced or it decreases with time. When citric acid (citrate) is added to myeloperoxidase, reduction in myeloperoxidase activity during lyophilization and lowering in activity with time during storage period are suppressed, and the solubility of pharmaceutical preparation of myeloperoxidase is also raised. n COPYRIGHT: (C)1984,JPO&Japio
priorityDate 1982-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID311
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448956568
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17942768
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6224
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474445
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409206349

Total number of triples: 26.